Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PU-H71 and Ruxolitinib in Myelofibrosis
NCT03373877Phase 1Terminated
- Sponsor
- Samus Therapeutics
- Start
- May 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zelavespib in myelofibrosis (MF) (4 arms), sponsored by Samus Therapeutics. Primary endpoints: Incidence of adverse events at 12 months, Maximum Tolerated Dose of PU-H71 at 7 months and 6 more. Started May 2018; status: terminated.
02
Drugs
zelavespib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03373877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373877.